Skip to content

Investigation for Inflammation,Metabolism and Potential Pathogenesis in Cognitive Impairment Population

Investigation for Inflammation,Metabolism and Potential Pathogenesis in Cognitive Impairment Population

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111963
Enrollment
Unknown
Registered
2025-11-07
Start date
2025-11-10
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer‘s disease

Interventions

Participant group and control group:None

Sponsors

Quangang District General Hospital, First Affiliated Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Age 40–90 years; 2.Primary or comorbid diagnosis of cognitive impairment, presenting with memory decline, inattention, executive dysfunction, or personality changes; 3.Complete cognitive assessments, able to complete MoCA (or Mini-MoCA) and MMSE; 4.Able to communicate and complete questionnaires independently or with family assistance (including PHQ-9); 5.Written informed consent obtained from the participant or legal guardian, with brain MRI results available within the past 12 months and blood test available within 3 months.

Exclusion criteria

Exclusion criteria: 1.History of stroke or cerebrovascular disease: confirmed ischemic or hemorrhagic stroke, severe intracranial arterial stenosis (>=70%) or occlusion, or focal neurological deficits related to vascular lesions; 2.Moderate-to-severe depression (PHQ-9 > 10) or acute phase of severe psychiatric disorders; 3.Other conditions known to cause cognitive impairment: infectious (e.g., neurosyphilis, HIV), endocrine/metabolic (e.g., hypothyroidism, severe anemia, vitamin B12 deficiency), genetic/degenerative (e.g., CJD, NIID, SCA, WD, PD); 4.Malignancy treatment: current or within the past 2 years, including surgery, radiotherapy, chemotherapy, or immunotherapy; 5.Autoimmune diseases or immunomodulatory therapy: rheumatoid arthritis, systemic lupus erythematosus, post–organ transplantation, or ongoing/past use of corticosteroids or immunosuppressants; 6.Significant data incompleteness or refusal to provide complete study information.

Design outcomes

Primary

MeasureTime frame
p-tau 217;IL-6;MOCA score;Glial fibrillary acidic protein;

Countries

China

Contacts

Public ContactWang Guomin

Quangang General Hospital, the First Affiliated Hospital,Fujian Medical University

guominwang69@fjmu.edu.cn+86 138 5978 7545

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026